 | |
| Clinical data | |
|---|---|
| Other names | TC-5619 |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C22H23N3O2 |
| Molar mass | 361.445 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Bradanicline (INN;[1] development codeTC-5619) is a drug which was beingdeveloped byTargacept that acts as apartial agonist at theα7 subtype of the neuralnicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept andAstraZeneca as a potential treatment forschizophrenia andattention deficit disorder.[2] Phase Iclinical trials were completed successfully, and it was in phase II trials.[3]
In May 2011,AstraZeneca declined to exercise its right to license the compound.[4] In September 2012, Targacept ended its development of badanicline for the purpose of treating ADHD in adults.[5] It was being studied for cognitive and memory enhancement.[6]
Bradanicline was discontinued forAlzheimer's disease and cognitive impairment in schizophrenia in late-2013.[7] It was also discontinued for ADHD.[7]
